AA
INDV icon

AlphaCentric Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

AlphaCentric Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-242,500
Closed -$2.36M – 250
2024
Q3 		$2.36M Buy
+242,500
New +$2.84M 1.76% 9

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

AlphaCentric Advisors's INDV Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Indivior Pharmaceuticals (INDV) in Q4 2024, closing a stake of 242,500 shares — an estimated $2.36M sold.

AlphaCentric Advisors first reported a position in INDV in Q3 2024 and held it in 1 quarter. The position peaked at $2.36M in Q3 2024. 113 funds tracked by Wall St. Rank hold INDV as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Indivior Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 242,500 Indivior Pharmaceuticals shares in Q4 2024, an estimated $2.36M.
  • AlphaCentric Advisors first reported a position in Indivior Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's Indivior Pharmaceuticals position peaked at $2.36M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.